Low molecular weight heparin mediating targeting of lymph node metastasis based on nanoliposome and enzyme-substrate interaction

Carbohydrate Polymers

Volumn 122, Issue , 2015, Pages 26-38

  Ye, Tiantian ^a   Jiang, Xuewei ^a   Li, Jing ^b   Yang, Rui ^a   Mao, Yuling ^a   Li, Kai ^a   Li, Liang ^a   Chen, Fen ^a   Yao, Jianhua ^a   Wu, Yingliang ^a   Yang, Xinggang ^a   Wang, Shujun ^a   Pan, Weisan ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Heparanase; Low molecular weight heparin; Lymph node metastasis; Nanoliposome; Targeting

Indexed keywords

DRUG PRODUCTS; MOLECULAR WEIGHT; PATHOLOGY; POLYSACCHARIDES; TUMORS;

HEPARANASE; LOW-MOLECULAR WEIGHT HEPARINS; LYMPH NODE METASTASIS; NANOLIPOSOME; TARGETING;

BODY FLUIDS;

MUS;

BETA GLUCURONIDASE; HEPARANASE; LIPOSOME; LOW MOLECULAR WEIGHT HEPARIN; NANOMATERIAL; WATER;

ANIMAL; BLOOD FLOW; CHEMISTRY; DRUG EFFECTS; DRUG RELEASE; DRUG STABILITY; GENE EXPRESSION REGULATION; HUMAN; LYMPH NODE; LYMPH NODE METASTASIS; METABOLISM; MOUSE; PATHOLOGY; SOLUBILITY; TISSUE DISTRIBUTION; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE; VASCULARIZATION;

ANIMALS; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; DRUG LIBERATION; DRUG STABILITY; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCURONIDASE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; LIPOSOMES; LYMPH NODES; LYMPHATIC METASTASIS; MICE; NANOSTRUCTURES; REGIONAL BLOOD FLOW; SOLUBILITY; TISSUE DISTRIBUTION; WATER;

EID: 84921364281     PISSN: 01448617     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.carbpol.2014.12.061     Document Type: Article

References (42)

1. Arpicco, S., Lerda, C., Dalla Pozza, E., Costanzob, C., Tsapisc, N., Stella, B., et al. (2013). Hyaluronic acid-coated liposomes for active targeting of gemcitabine. European Journal of Pharmaceutics and Biopharmaceutics, 85, 373-380.
2. Asati, A., Santra, S., Kaittanis, C., & Perez, J. M. (2010). Surface-charge-dependent cell localization and cytotoxicity of cerium oxide nanoparticles. ACS Nano, 4, 5321-5331.
3. Cai, S., Yang, Q., Bagby, T. R., & Forrest, M. L. (2011). Lymphatic drug delivery using engineered liposomes and solid lipid nanoparticle. Advanced Drug Delivery Reviews, 63, 901-908.
4. Ciccone, M. M., Cortese, F., Corbo, F., Corrales, N. E., Al-Momen, A. K., Silva, A., et al. (2014). Bemiparin, an effective and safe low molecular weight heparin: A review. Vascular Pharmcology, 62, 32-37.
5. Dadras, S. S., Lange-Asschenfeldt, B., Velasco, P., Nguyen, L., Vora, L., Muzikansky, A., et al. (2005). Tumor lymphangiogenesis predicts melanoma metastasis to sentinel lymph nodes. Journal of Cutaneous Pathology, 32, 84.
6. Dafni, H., Cohen, B., Ziv, K., Israely, T., Goldshmidt, O., Nevo, N., et al. (2005). The role of heparanase in lymph node metastatic dissemination: Dynamic contrast-enhanced MRI of Eb lymphoma in mice. Neoplasia, 7, 224-233.
7. Fröhlich, E. (2012). The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles. International Journal of Nanomedicine, 7, 5577.
8. European Pharmacopoeia 7.0. (2010). European directorate for the quality of medicines (EDQM). Strasbourg, France: Council of Europe (01/2008:1097.Enoxaparin Sdium)
9. Gupta, A., Mandal, D., Ahmadibeni, Y., Parang, K., & Bothun, G. (2011). Hydrophobicity drives the cellular uptake of short cationic peptide ligands. European Biophysics Journal, 40, 727-736.
10. Hawley, A. E., Davis, S. S., & Illum, L. (1995). Targeting of colloids to lymph nodes: Influence of lymphatic physiology and colloidal characteristics. Advanced Drug Delivery Reviews, 17, 129-148.
11. Ihaddadene, R., Le Gal, G., Delluc, A., & Carrier, M. (2014). Dose escalation of low molecular weight heparin in patients with recurrent cancer-associated thrombosis. Thrombosis Research, 134, 93-95.
12. Inagaki, J., Takahashi, K., Ogawa, H., Asano, K., Faruk Hatipoglu, O., Zeynel Cilek, M., et al. (2014). ADAMTS1 inhibits lymphangiogenesis by attenuating phosphorylation of the lymphatic endothelial cell-specific VEGF receptor. Experimental Cell Research, 323, 263-275.
13. Ingle, R. G., & Agarwal, A. S. (2014). A world of low molecular weight heparins (LMWHs) enoxaparin as a promising moiety - A review. Carbohydrate Polymers, 106, 148-153.
14. Ji, R. C. (2006). Lymphatic endothelial cells, lymphangiogenesis, and extracellular matrix. Lymphatic Research and Biology, 4, 83-100.
15. Jin, L., Nakajima, M., & Nicolson, G. L. (1990). Immunochemical localization of heparanase in mouse and human melanomas. International Journal of Cancer, 45, 1088-1095.
16. Klerk, C. P., Smorenburg, S. M., Otten, H. M., Lensing, A. W., Prins, M. H., Piovella, F., et al. (2005). The effect of low molecular weight heparin on survival in patients with advanced malignancy. Journal of Clinical Oncology, 23, 2130-2135.
17. Koyama, H., Kobayashi, N., Harada, M., Takeoka, M., Kawai, Y., Sano, K., et al. (2008). Significance of tumor-associated stroma in promotion of intratumoral lymphangiogenesis: Pivotal role of a hyaluronan-rich tumor microenvironment. American Journal of Pathology, 172, 179-193.
18. Lapierre, F., Holme, K., Lam, L., Tressler, R. J., Storm, N., Wee, J., et al. (1996). Chemical modifications of heparin that diminish its anticoagulant but preserve its heparanase-inhibitory, angiostatic, anti-tumor and anti-metastatic properties. Glycobiology, 6, 355-366.
19. Lee, K., Lee, H., Bae, K. H., & Park, T. G. (2010). Heparin immobilized gold nanoparticles for targeted detection and apoptotic death of metastatic cancer cells. Biomaterials, 31, 6530-6536.
20. Nakajima, M., Irimura, T., Di Ferrante, N., & Nicolson, G. L. (1984). Metastatic melanoma cell heparanase. Characterization of heparan sulfate degradation fragments produced by B16 melanoma endoglucuronidase. Journal of Biological Chemistry, 259, 2283-2290.
21. Nakajima, M., Irimura, T., & Nicolson, G. L. (1986). Tumor metastasis-associated heparanase (heparan sulfateb-endoglycosidase) in human melanoma cells. Cancer Letter, 31, 277-283.
22. Nakajima, M., Irimura, T., & Nicolson, G. L. (1988). Heparanases and tumor metastasis. International Journal of Biochemistry & Cell Biology, 36, 157-167.
23. Nasser, N. J., Sarig, G., Brenner, B., Nevo, E., Goldshmidt, O., Zcharia, E., et al. (2006). Heparanase neutralizes the anticoagulation properties of heparin and low-molecular-weight heparin. Journal of Thrombosis and Haemostasis, 4, 560-565.
24. Nehs, M. A., Nagarkatti, S., Nucera, C., Hodin, R. A., & Parangi, S. (2010). Thyroidectomy with neoadjuvant PLX4720 extends survival and decreases tumor burden in an orthotopic mouse model of anaplastic thyroid cancer. Surgery, 148, 1154-1162.
25. Nilasaroya, A., Martens, P. J., & Whitelock, J. M. (2012). Enzymatic degradation of heparin-modified hydrogels and its effect on bioactivity. Biomaterials, 33, 5534-5540.
26. Ogawa, F., Amano, H., Ito, Y., Matsui, Y., Hosono, K., Kitasato, H., et al. (2014). Aspirin reduces lung cancer metastasis to regional lymph nodes. Biomedicine & Pharmacotherapy, 68, 79-86.
27. Reiland, J., Sanderson, R. D., Waguespack, M., Barker, S. A., Long, R., Carson, D. D., et al. (2004). Heparanase degrades syndecan-1 and perlecan heparan sulfate: Functional implications for tumor cell invasion. Journal of Biological Chemistry, 27, 8047-8055.
28. Parish, C. R., Freeman, C., & Hulett, M. D. (2001). Heparanase: A key enzyme involved in cell invasion. Biochimica et Biophysica Acta-Reviews on Cancer, 1471, 99-108.
29. Rinderknecht, M., & Detmar, M. (2008). Tumor lymphangiogenesis and melanoma metastasis. Journal of Cellular Physiology, 216, 347-354.
30. Shen, J., Zhan, C., Xie, C., Meng, Q., Gu, B., Li, C., et al. (2011). Poly(ethylene glycol)-block-poly(D,L-lactide acid) micelles anchored with angiopep-2 for brain-targeting delivery. Journal of Drug Targeting, 19, 197-203.
31. Smorenburg, S. M., & Van Noorden, C. J. (2001). The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacological Reviews, 53, 93-106.
32. Stacker, S. A., Baldwin, M. E., & Achen, M. G. (2002). The role of tumor lymphangiogenesis in metastatic spread. FASEB Journal, 16, 922-934.
33. Terwisscha van Scheltinga, C. E. J., Spronk, P., van Rosmalen, J., Wijnen, M. H., Heij, H. A., van Baren, R., et al. (2014). Diagnosis and treatment of lymph node metastases in pediatric rhabdomyosarcoma in the Netherlands: A retrospective analysis. Journal of Pediatric Surgery, 49, 416-419.
34. Tiantian, Y., Wenji, Z., Mingshuang, S., Rui, Y., Shuangshuang, S., Yuling, M., et al. (2014). Study on intralymphatic-targeted hyaluronic acid-modified nanoliposome: Influence of formulation factors on the lymphatic targeting. International Journal of Pharmaceutics, 471, 245-257.
35. Torchilin, V. (2011). Tumor delivery of macromolecular drugs based on the EPR effect. Advanced Drug Delivery Reviews, 63, 131-135.
36. Volodkin, D., Mohwald, H., Voegel, J. C., & Ball, V. (2007). Coating of negatively chargedliposomes by polylysine: Drug release study. Journal of Controlled Release, 117, 111-120.
37. Vlodavsky, I., Mohsen, M., Lider, O., Svahn, C. M., Ekre, H. P., Vigoda, M., et al. (1993). Inhibition of tumor metastasis by heparanase inhibiting species of heparin. Invasion & Metastasis, 14, 290-302.
38. Vlodavsky, I., Ilan, N., Nadir, Y., Brenner, B., Katz, B., Naggi, A., et al. (2007). Heparanase, heparin and the coagulation system in cancer progression. Thrombosis Research, 120, 112-120.
39. Xiao, L., Xiong, X. Q., Sun, X. H., Zhu, Y. H., Yang, H., Chen, H. B., et al. (2011). Role of cellular uptake in the reversal of multidrug resistance by PEG-b-PLA polymeric micelles. Biomaterials, 32, 5148-5157.
40. Yang, X., Li, Y., Li, M., Zhang, L., Feng, L. X., & Zhang, N. (2013). Hyaluronic acid-coated nanostructured lipid carriers for targeting paclitaxel to cancer. Cancer Letter, 334, 338-345.
41. Yan, Z., Wang, F., Wen, Z., Zhan, C., Feng, L., Liu, Y., et al. (2012). LyP-1-conjugated PEGylated liposomes: A carrier system for targeted therapy of lymphatic metastatic tumor. Journal of Controlled Release, 157, 118-125.
42. Yoshihara, E., Smeets, A., Laenen, A., Reynders, A., Soens, J., Ongeval, C. V., et al. (2013). Predictors of axillary lymph node metastases in early breast cancer and their applicability in clinical practice. Breast, 22, 357-361.